Table 3.
Observations related to glycemic control and weight alterations.
| Parameters | Number of patients (N = 5695)* |
|---|---|
| Up-titration or down-titration of metformin done during treatment, n (%) [n = 5693] | 2370 (41.6) |
| Dosage up-titration | 2295 (96.8) |
| Dosage down-titration | 75 (3.2) |
| HbA1c level before treatment initiation, n (%) [n = 5543] | |
| <7.5 | 835 (15.1) |
| 7.5-8.0 | 2289 (41.3) |
| 8.0-8.5 | 1307 (23.6) |
| 8.5-9.0 | 518 (9.3) |
| 9.0-9.5 | 341 (6.1) |
| 9.5-10.0 | 185 (3.3) |
| <10.0 | 68 (1.2) |
| Patients with glycemic goal achieved, n (%) [n = 5693] | 5193 (91.2) |
| Patients with weight changes during the therapy, n (%) [n = 5672] | 4196 (73.9) |
| (a) Decreased weight (kg) | |
| 0-2 | 2415 (57.6) |
| 2-4 | 905 (21.6) |
| >4 | 161 (3.8) |
| (b) Increased weight (kg) | |
| 0-2 | 453 (10.8) |
| 2-4 | 239 (5.7) |
| >4 | 23 (0.5) |
| Adverse events reported, n | [n = 156] |
| Gastritis | 50 |
| Dyspepsia | 22 |
| GI disease | 19 |
| Nausea | 18 |
| Diarrhea | 17 |
| Vomiting | 14 |
| Dizziness | 10 |
| Others | 6 |
Abbreviations: FPG, fasting plasma glucose; GI, gastrointestinal; HbA1c, glycated hemoglobin; PPG, postprandial plasma glucose.
Other adverse events include abdominal discomfort and inadequate bowel movement, heart burn, constipation.
*
N = 5695, unless otherwise specified. Other reasons include combination of HbA1c, FPG, PPG, weight, and cost.